RT Journal Article
SR Electronic
T1 Topographic Heterogeneity of Lung Microbiota in End-Stage Idiopathic Pulmonary Fibrosis: The Microbiome in Lung Explants-2 (MiLEs-2) Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.05.20031021
DO 10.1101/2020.03.05.20031021
A1 Eleanor B Valenzi
A1 Haopu Yang
A1 John C Sembrat
A1 Libing Yang
A1 Spencer Winters
A1 Rachel Nettles
A1 Daniel J Kass
A1 Shulin Qin
A1 Xiaohong Wang
A1 Michael M Myerburg
A1 Barbara Methé
A1 Adam Fitch
A1 Jonathan K Alder
A1 Panayiotis V Benos
A1 Bryan J McVerry
A1 Mauricio Rojas
A1 Alison Morris
A1 Georgios D Kitsios
YR 2020
UL http://medrxiv.org/content/early/2020/03/06/2020.03.05.20031021.abstract
AB Background Lung microbiota profiles in patients with early idiopathic pulmonary fibrosis (IPF) have been associated with disease progression; however, the topographic heterogeneity of lung microbiota and their roles in advanced IPF are unknown.Methods We sampled subpleural tissue from up to three lobes as well as airway-based specimens (bronchial washings and airway tissue) in patients with IPF, connective tissue disease-associated interstitial lung disease (CTD-ILD), cystic fibrosis (CF), and chronic obstructive pulmonary disease (COPD) and donor lungs deemed unsuitable for transplant (controls). We quantified bacterial load and profiled communities by polymerase chain reaction (PCR) amplification and sequencing of the 16S rRNA gene.Findings Explants from 62 IPF, 15 CTD-ILD, 20 CF, 20 COPD and 20 control patients were included. Airway-based samples had higher bacterial load compared to distal parenchymal tissue across all patient groups. IPF basilar tissue had much lower bacterial load compared to CF and control lungs (p<0.001). Among patients with IPF, no differences in microbial community profiles were found between parenchymal tissue samples from different lobes. With Dirichlet multinomial models, a cluster of IPF patients (29%) with distinct composition, high bacterial load and low alpha diversity was identified, exhibiting higher odds for acute exacerbation of IPF or death.Interpretation IPF explants exhibited low biomass in the distal parenchyma of all three lobes with higher bacterial load in the airways. The discovery of a distinct subgroup of IPF patients with higher bacterial load and worse clinical outcomes supports investigation of personalized medicine approaches for microbiome-targeted interventions.Key MessagesWhat is the key question?Bronchoalveolar lavage microbiome profiles in early idiopathic pulmonary fibrosis (IPF) have been associated with disease progression, but the regional heterogeneity of resident microbiota in end-stage IPF has not been defined.What is the bottom line?IPF explants demonstrate higher bacterial load in airway compared to parenchymal samples, but no differences in between apical or basilar parenchymal samples. A subgroup of patients with higher bacterial load and respiratory pathogen abundance was associated with worse clinical outcomes.Why read on?Patient-specific heterogeneity in the lung microbiome of IPF supports the need for personalized microbiome-targeted interventions in IPF.Competing Interest StatementDr. Bryan J. McVerry is a consultant for The VeraMedica Institute, LLC and receives research funding from Bayer Pharmaceuticals, Inc. Dr. Georgios D. Kitsios receives research funding from Karius, Inc. The other authors have no conflicts of interest to declare.Funding StatementNational Institutes of Health [K23 HL139987 (GDK); U01 HL098962 (AM); U01 HL137159 (PVB); R01 HL127349 (PVB); K24 HL123342 (AM); R01 HL123766 (MR), RO1 HL126990 (DK), T32 HL007563-31 (EV), CFF RDP to the University of Pittsburgh (MM)], Breathe Pennsylvania Lung Health Research Grant (GDK).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified sequencing data have been submitted to Sequence Read Archive (SRA) database, with BioSample accession number of SAMN13906474-13906711.